WFRF:(Petrie KJ)
Sökning: WFRF:(Petrie KJ) > What Should Clinici...
- 4 av 4
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04306naa a2200637 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:145353175 | |
| 003 | SwePub | |
| 008 | 240701s2020 | |||||||||||000 ||eng| | |
| 009 | oai:DiVA.org:uu-488777 | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1453531752 URI |
| 024 | 7 | a https://doi.org/10.1159/0005107382 DOI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4887772 URI |
| 040 | a (SwePub)kid (SwePub)uu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Evers, AWM4 aut |
| 245 | 1 0 | a What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus |
| 264 | c 2020-10-19 | |
| 264 | 1 | b S. Karger AG,c 2020 |
| 520 | a <b><i>Introduction:</i></b> Clinical and laboratory studies demonstrate that placebo and nocebo effects influence various symptoms and conditions after the administration of both inert and active treatments. <b><i>Objective:</i></b> There is an increasing need for up-to-date recommendations on how to inform patients about placebo and nocebo effects in clinical practice and train clinicians how to disclose this information. <b><i>Methods:</i></b> Based on previous clinical recommendations concerning placebo and nocebo effects, a 3-step, invitation-only Delphi study was conducted among an interdisciplinary group of internationally recognized experts. The study consisted of open- and closed-ended survey questions followed by a final expert meeting. The surveys were subdivided into 3 parts: (1) informing patients about placebo effects, (2) informing patients about nocebo effects, and (3) training clinicians how to communicate this information to the patients. <b><i>Results:</i></b> There was consensus that communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities. <b><i>Conclusions:</i></b> The current 3-step Delphi study provides consensus-based recommendations and practical considerations for disclosures about placebo and nocebo effects in clinical practice. Future research is needed on how to optimally tailor information to specific clinical conditions and patients’ needs, and on developing standardized disclosure training modules for clinicians. | |
| 700 | 1 | a Colloca, L4 aut |
| 700 | 1 | a Blease, Charlotteu General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA, USA4 aut0 (Swepub:uu)chabl597 |
| 700 | 1 | a Gaab, J4 aut |
| 700 | 1 | a Jensen, KBu Karolinska Institutet4 aut |
| 700 | 1 | a Atlas, LY4 aut |
| 700 | 1 | a Beedie, CJ4 aut |
| 700 | 1 | a Benedetti, F4 aut |
| 700 | 1 | a Bingel, U4 aut |
| 700 | 1 | a Buchel, C4 aut |
| 700 | 1 | a Bussemaker, J4 aut |
| 700 | 1 | a , en Colagiuri4 aut |
| 700 | 1 | a Crum, AJ4 aut |
| 700 | 1 | a Finniss, DG4 aut |
| 700 | 1 | a Geers, AL4 aut |
| 700 | 1 | a Howick, J4 aut |
| 700 | 1 | a Klinger, R4 aut |
| 700 | 1 | a Meeuwis, SH4 aut |
| 700 | 1 | a Meissner, K4 aut |
| 700 | 1 | a Napadow, V4 aut |
| 700 | 1 | a Petrie, KJ4 aut |
| 700 | 1 | a Rief, W4 aut |
| 700 | 1 | a Smeets, I4 aut |
| 700 | 1 | a Wager, TD4 aut |
| 700 | 1 | a Wanigasekera, V4 aut |
| 700 | 1 | a Vase, L4 aut |
| 700 | 1 | a Kelley, JM4 aut |
| 700 | 1 | a Kirsch, I4 aut |
| 710 | 2 | a Karolinska Institutetb General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA, USA4 org |
| 773 | 0 | t Psychotherapy and psychosomaticsd : S. Karger AGg 90:1, s. 49-56q 90:1<49-56x 1423-0348x 0033-3190 |
| 856 | 4 | u https://www.karger.com/Article/Pdf/510738 |
| 856 | 4 | u https://doi.org/10.1159/000510738y Fulltext |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:145353175 |
| 856 | 4 8 | u https://doi.org/10.1159/000510738 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-488777 |
Hitta via bibliotek
- Psychotherapy and psychosomatics (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 4 av 4
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Evers, AWM
- Colloca, L
- Blease, Charlott ...
- Gaab, J
- Jensen, KB
- Atlas, LY
- visa fler...
- Beedie, CJ
- Benedetti, F
- Bingel, U
- Buchel, C
- Bussemaker, J
- , en Colagiuri
- Crum, AJ
- Finniss, DG
- Geers, AL
- Howick, J
- Klinger, R
- Meeuwis, SH
- Meissner, K
- Napadow, V
- Petrie, KJ
- Rief, W
- Smeets, I
- Wager, TD
- Wanigasekera, V
- Vase, L
- Kelley, JM
- Kirsch, I
- visa färre...
- Artiklar i publikationen
- Psychotherapy an ...
- Av lärosätet
- Karolinska Institutet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
